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Bioreactor systems will likely play a key role in establishing regulatory compliant and
cost‐effective production systems for manufacturing engineered tissue grafts for clin-
ical applications. However, the automation of bioreactor systems could become con-
siderably more complex and costly due to the requirements for additional storage and
liquid handling technologies if unstable supplements are added to the culture medium.
Ascorbic acid (AA) is a bioactive supplement that is commonly presumed to be essen-
tial for the generation of engineered cartilage tissues. However, AA can be rapidly oxi-
dized and degraded. In this work, we addressed whether human nasal chondrocytes
can redifferentiate, undergo chondrogenesis, and generate a cartilaginous extracellu-
lar matrix when cultured in the absence of AA. We found that when chondrocytes
were cultured in 3D micromass pellets either with or without AA, there were no sig-
nificant differences in their chondrogenic capacity in terms of gene expression or the
amount of glycosaminoglycans. Moreover, 3D pellets cultured without AA contained
abundant collagen Types II and I extracellular matrix. Although the amounts of Colla-
gens II and I were significantly lower (34% and 50% lower) than in pellets cultured
with AA, collagen fibers had similar thicknesses and distributions for both groups, as
shown by scanning electron microscopy imaging. Despite the reduced amounts of col-
lagen, if engineered cartilage grafts can be generated with sufficient properties that
meet defined quality criteria without the use of unstable supplements such as AA,
bioreactor automation requirements can be greatly simplified, thereby facilitating
the development of more compact, user‐friendly, and cost‐effective bioreactor‐based
manufacturing systems.
KEYWORDS
ascorbic acid, cartilage, collagen, hydroxyproline, nasal chondrocytes, tissue engineering1 | INTRODUCTION
While engineered tissue grafts hold immense therapeutic potential, a
number of obstacles currently exist that inhibit the translation of sci-
entific innovation into commercially viable therapies. Among the
obstacles that must be addressed are crucial challenges associatedwileyonlinelibrary.com/journwith the manufacturing of engineered grafts (Lysaght, Jaklenec, &
Deweerd, 2008; Martin, Simmons, & Williams, 2014). Bioreactor sys-
tems, which automate and standardize bioprocesses, have the poten-
tial to overcome key manufacturing challenges and facilitate
regulatory compliant and cost‐effective production of engineered tis-
sue grafts (Martin, Smith, & Wendt, 2009; Ratcliffe & Niklason, 2002).
The automation of bioreactor systems, however, can become con-
siderably complex due to the complicated liquid handling and storage
conditions imposed by unstable compounds used in many cultureCopyright © 2018 John Wiley & Sons, Ltd.al/term 1
2 ASNAGHI ET AL.medium formulations. We have previously found the growth factor
TGF‐β to maintain high bioactivity even when stored at 37 °C for up
to 3 weeks (Vonwil, et al., 2008); however, the stability of other
medium supplements should also be assessed. Ascorbic acid (AA) is
a bioactive supplement typically used in the generation of engineered
cartilage, which can be rapidly oxidized to dehydroascorbic acid and
further degraded by oxidation or hydrolysis, resulting in short‐time
stability (Chepda, Cadau, Girin, Frey, & Chamson, 2001; Fisher &
Naughton, 2004; Kurano, Kurano, Leist, & Fiechter, 1990). Several
AA derivatives have been developed with protective groups against
degradation, such as the more stable but equally bioactive ascorbic
acid‐2‐phosphate (AA2P; Takamizawa et al., 2004). Despite its
increased stability, AA2P is typically added from frozen aliquots at
every medium exchange, which drastically complicates bioprocess
automation due to the additional need for freezing/thawing modules
and the associated liquid handling technology, therefore presenting
significant obstacles towards establishing a (a) compact, (b) user‐
friendly, and (c) cost‐effective bioreactor‐based manufacturing
system.
In addition to being a notable antioxidant, AA is thought to induce
chondrogenesis via an upregulation of collagen expression and is there-
fore added in most protocols for chondrogenic differentiation (Altaf,
Hering, Kazmi, Yoo, & Johnstone, 2006; Cigan et al., 2013; Ibold,
et al., 2009); an essential process in the production of engineered carti-
lage grafts. Moreover, AA is involved in the synthesis of collagens,
including collagen Type II, a key protein in articular hyaline cartilage
(Buckwalter & Mankin, 1998). In particular, AA serves as a cofactor
for the enzymes prolyl hydroxylase and lysyl hydroxlase, which are
responsible for the hydroxylation of proline and lysine residues of the
collagen propeptide. This hydroxylation is essential for the collagen
monomer cross‐linking and collagen triple helix stability (Barnes &
Kodicek, 1972; Englard & Seifter, 1986; Kavitha & Thampan, 2008).
Nevertheless, it has been shown in a number of model systems
that alternative biomolecules are available which could replace AA as
an antioxidant and cofactor (e.g., glutathione; Barnes & Kodicek,
1972; Englard & Seifter, 1986; Flashman, Davies, Yeoh, & Schofield,
2010; Martensson, Han, Griffith, & Meister, 1993; Nytko et al.,
2011), and thus, AA may not be required for the generation of hyaline
cartilage tissues.
In this work, we addressed whether expanded human nasal
chondrocytes can redifferentiate, undergo chondrogenesis, and gener-
ate a cartilagenous extracellular matrix when cultured in vitro in the
absence of AA. With an increased understanding of the effects of
AA on cartilage tissue engineering, efficient supplementation regimes
can be established to define automation requirements, while ensuring
graft quality.2 | MATERIALS AND METHODS
2.1 | Cell isolation and expansion
Samples of human cartilage were collected from the nasal septum of
10 patients undergoing rhinoplasty (mean age 37 years, range 21–
63 years), after informed consent and in accordance with the localethical commission (EKBB; Ref.# 78/07). Cartilage biopsies were
digested using 0.15% Collagenase II (Worthington, UK) for 22 hr at
37 °C as previously described (Jakob et al., 2003). After digestion, cells
were plated in tissue culture flasks at a density of 1 × 104 cells/cm2
and cultured in medium consisting of Dulbecco's Modified Eagle's
Medium containing 4.5 mg/ml D‐glucose and 0.1 mM nonessential
amino acids (DMEM, Gibco, Life Technologies, Switzerland), 10% fetal
bovine serum (FBS), 1 mM sodium pyruvate, 100 mM HEPES buffer,
100 U/ml penicillin, 100 μg/ml streptomycin, and 0.29 mg/ml L‐gluta-
mine (all from Gibco), supplemented with 1 ng/ml transforming growth
factor beta‐1 and 5 ng/ml fibroblast growth factor‐2 (both from R&D
Systems, UK) at 37 °C and 5% CO2 in a humidified incubator (Thermo
Scientific Heraeus, USA; Jakob et al., 2001). When approaching 80%
confluence, cells were detached using 0.05% trypsin‐EDTA (Gibco),
resuspended in FBS containing 10% dimethyl sulfoxide, transferred
to cryovials (Sarstedt, Germany), and stored in liquid nitrogen tanks
until further use.2.2 | Chondrogenic redifferentiation
Chondrocytes from frozen aliquots were expanded until Passage 2 and
redifferentiated by culturing as 3D micromass pellets, which were
formed by centrifuging 5E + 05 cells at 300 × g in 1.5 ml conical tubes
(Sarstedt). 3D micromass pellets were cultured for 2 weeks either with
or without 100 μM AA2P (Sigma; experimental groups: +AA2P or
−AA2P, respectively) in chondrogenic serum‐free medium consisting
of DMEM containing 1 mM sodium pyruvate, 100 mM HEPES buffer,
100 U/ml penicillin, 100 μg/ml streptomycin, 0.29 g/ml L‐glutamine,
1.25 mg/ml human serum albumin (CSL Behring, Switzerland), and
100 nM dexamethasone (Sigma, Switzerland), supplemented with
10 ng/ml transforming growth factor beta‐1, ITS+1 (10 μg/ml insulin,
5.5 μg/ml transferrin, 5 ng/ml selenium; Gibco), 0.5 mg/ml bovine
serum albumin (Sigma), and 4.7 μg/ml linoleic acid (Sigma). For an
additional experimental group, micromass pellets were cultured with
AA2P, and the concentration of AA2P remaining in the culture
medium was readjusted to the initial level of 100 μM each day (exper-
imental group: Daily AA2P), based on measurements of AA2P (see
Section 2.3). As negative controls for chondrogenic redifferentiation,
one group of micromass pellets was cultured for 2 weeks without
AA2P and without ITS+1 (experimental group: −AA2P −ITS). For all
experimental groups, micromass pellet culture medium was changed
twice weekly.2.3 | AA measurements
AA2P was quantified in chondrogenic medium (both in serum‐free
medium and in 10% FBS containing medium), which was stored at
4 °C or 37 °C for up to 14 days (0, 1, 2, 4, 7, 10, and 14 days) using
the ferric reducing ascorbate assay kit (FRASC; BioVision, Switzer-
land), according to the manufacturer's instructions with an additional
step in order to measure the 2‐phosphate form. In addition, AA2P
was also quantified in the spent medium of +AA2P micromass pellet
cultures at 0, 1, 2, and 3 days. Briefly, to transform AA2P into measur-
able AA, samples were first incubated with 1unit/100 μl of alkaline
phosphatase (Sigma, Switzerland) for 10 min at 37 °C. This step was
ASNAGHI ET AL. 3omitted when measuring the medium concentration of AA without the
2‐phosphate group. Ascorbate oxidase or water was then added to
generate the AA depleted background or the total oxidant group,
respectively. After addition of the AA reaction mix, absorbance at
593 nm was measured and the concentration of AA2P or AA was cal-
culated from the difference of the total oxidant and the AA depleted
group based on an AA standard curve.2.4 | Histology and immunohistochemistry
Micromass pellets were fixed overnight in 4% formalin and embedded
in paraffin. Sections 5 μm in thickness were stained with Safranin‐O
for glycosaminoglycans (GAG) and hematoxylin as a nuclear
counterstaining. Immunohistochemistry against collagen Type I
(No.0863170, MPBiomedicals, France) and collagen Type II
(No.0863171, MPBiomedicals) was performed using the Vectastain
ABC kit (Vector Labs, USA) with haematoxylin counterstaining as pre-
viously described (Scotti et al., 2010). Terminal deoxynucleotidyl
transferase dUTP nick end labelling (TUNEL) with an Alexa Fluor 647
dye (Click‐iT TUNEL assay; Molecular Probes, Switzerland) was per-
formed on formalin‐fixed paraffin‐embedded sections, according to
the manufacturer's instructions. A positive control with DNA strand
breaks was generated by 30 min incubation at room temperature with
1 unit of DNase I (Molecular Probes). Immunofluorescence staining
against collagenType II was performed on OCT (CellPath, UK) embed-
ded 10 μm thick cryosections using the collagen Type II primary anti-
body (MPBiomedicals, France) and a goat anti‐mouse Alexa Fluor
546 secondary antibody (Invitrogen), with DAPI as a nuclear
counterstain.2.5 | Quantitative RT‐PCR
mRNA of chondrocytes was extracted using Quick‐RNA Miniprep
(Zymo Research, USA), according to the manufacturer's protocol.
DNaseI (Zymo Research) was used to remove trace DNA. Isolated
RNA was quantified using a NanoDrop spectrophotometer
(ThermoFischer Scientific). Reverse transcription into cDNA was done
from 3 μg of RNA by using 500 μg/ml random hexamers (Promega,
Switzerland) and 0.5 μl of 200UI/ml SuperScript III reverse transcrip-
tase (Invitrogen), in the presence of dNTPs. Real‐time PCR was carried
out on an ABI Prism 7700 Sequence Detection System (Perkin‐Elmer/
Applied Biosystems, Switzerland). After initial denaturation at 95 °C
for 10 min, cDNA was amplified for 40 cycles, each consisting of a
denaturation step at 95 °C for 15 s and an annealing/extension step
at 60 °C for 60 s. Primers and probes for aggrecan, versican, collagen
Type I, collagen Type II, and GAPDH were used with TaqMan Gene
Expression Master Mix (Applied Biosystems) as previously described
(Martin et al., 2001). Assay on‐Demand (Applied Biosystems) was used
to measure the expression of SOX9 (Hs00165814_m1). The threshold
cycle (Ct) value of the reference gene GAPDH was subtracted from
the Ct value of the gene of interest to derive ΔCt. The relative gene
expression of each group normalized to the cells after expansion was
calculated as 2‐ΔΔCt. Each sample was assessed at least in duplicate
for each gene of interest.2.6 | Biochemical analyses
Micromass pellets were digested in proteinase K (1 mg/ml proteinase
K in 50 mM Tris with 1 mM EDTA, 1 mM iodoacetamide, and 10 mg/
ml pepstatin A) for 16 hr at 56 °C. The sulphated glycosaminoglycan
(sGAG) content of pellets was determined by spectrophotometry
using dimethylmethylene blue, with chondroitin sulphate as a standard
(Barbosa et al., 2003). The DNA content of pellets was measured using
the CyQuant cell proliferation assay kit (Invitrogen), with calf thymus
DNA as a standard. The amount of sGAG in pellets was then normal-
ized to the DNA content. For hydroxyproline quantification, samples
were processed as previously described (Cigan et al., 2013;
Hofman, Hall, Cleaver, & Marshall, 2011). Briefly, proteinase K
digested samples were mixed with equal amounts of 12M HCl and
hydrolysed at 120 °C for 24 hr. Specimens were then transferred into
96‐well plates and left to dry before addition of acetate‐citrate
buffered chloramineT and incubation for 20 min at room temperature.
Dimethylaminobenzaldehyde was added and the plates heated for
20 min to 60 °C. Absorbance was then measured at 550 nm. Concen-
trations were calculated based on a hydroxyproline (Sigma) standard
curve.2.7 | Collagen quantification
Pellets were solubilized by an initial digestion in 25 μl of 2 mg/ml
TPCK‐treated bovine pancreatic trypsin (in 50 mM Tris HCl pH 7.5,
1 mM EDTA, 1 mM iodoacatamide, 20 μg/ml Pepstatin A), for 15 hr
at 37 °C. A further 25 μl of freshly prepared trypsin solution was
added, and digests were incubated for 2 hr at 65 °C, with intermittent
vortexing. Digests were then boiled for 15 min to destroy remaining
enzyme activity. The quantity of collagenType II was determined using
an inhibition ELISA with a mouse IgG monoclonal antibody to dena-
tured collagen Type II (Dickinson et al., 2005). Collagen Type I was
measured by inhibition ELISA using a rabbit antipeptide antibody to
collagen Type I (Hollander et al., 1994).2.8 | Scanning electron microscopy (SEM)
For SEM, pellets were fixed for 2 days in 0.1M cacodylate‐buffered 2%
glutaraldehyde at pH 7.2 at 25 °C, then glued onto aTeflon disc with a
rapidly curing epoxy glue (Araldite; Huntsman, UK). Next, the
specimens were placed in a cryostat microtome to trim off approxi-
mately 150 μm of the outermost cartilage layer parallel to the support
surface to assess the central region of the samples. Proteoglycans were
then extracted in 100 mM Soerensen's phosphate buffer (pH 7.2) con-
taining 1 mg/ml bovine hyaluronidase (Type I, Sigma), 1 mg/ml trypsin
(Type I, Sigma), and 0.01% NaN3 at 37 °C for 3 days. After dehydration
in graded ethanol series and critical point drying, samples were sputter‐
coated with 3–5 nm platinum and examined by SEM (Hitachi S‐4800
FEG, Japan), operated at 1.5–5 kV accelerating voltage in immersion
mode (Stolz et al., 2009; Strobel et al., 2010). The collagen fibers within
micromass pellets were assessed qualitatively based on the acquired
SEM images.
4 ASNAGHI ET AL.2.9 | Statistical analysis
Data are presented as mean and standard deviation of independent
experiments with cells from at least two different donors. For each
analysis, at least three replicate micromass pellets were used per con-
dition. Statistical analysis was performed using RStudio version
1.1.149 (RStudio, Boston, MA; http://www.rstudio.com). The effects
of the AA treatment groups were assessed using a linear mixed effect
model. Treatment group was defined as the fixed effect and cell donor
defined as the random effect. Measurement values were log10 trans-
formed and, then, fit with the mixed effect model using the R package
lme4. Differences were assessed using a one‐way ANOVA followed
by a post hoc Tukey test using the R package multcomp. Differences
between groups were considered statistically significant for p < .05.3 | RESULTS
3.1 | AA2P concentration in culture media
In order to test the availability of AA in chondrogenic medium formu-
lations, AA stability was determined in stored medium and spent pellet
culture medium, with or without FBS, for the 2‐week culture period
required for automated bioreactor‐engineered cartilage (Tonnarelli,
Santoro, Asnaghi, & Wendt, 2016). When media was supplemented
with AA, which lacks the protective 2‐phosphate group, levels were
below the detection limit in both stored and spent pellet culture
medium at all‐time points, indicating a rapid degradation and/or con-
sumption of this medium supplement (data not shown). For the
remainder of the study, we therefore exclusively tested media supple-
mented with AA2P, and not AA. In medium containing serum, AA2P
was rapidly degraded. AA2P was particularly unstable when stored in
medium containing serum at 37 °C, dropping to less than 10% of the
initial concentration within 24 hr (Figure 1a). In serum‐free culture
medium, the concentration of AA2P remained constant for 2 weeks
of storage, both at 4 and 37 °C. However, when culturing micromass
pellets in serum‐free culture medium, the concentration of AA2P
decreased by almost 50% within the first 24 hr of culture, and further
declined to less than 25% of the initial concentration by Day 3
(Figure 1b). Because a constant concentration of AA or AA2P was
not maintained in the presence of cultured chondrocytes withoutFIGURE 1 Availability of AA2P in stored medium and in micromass pellet
fetal bovine serum‐containing medium (CM) stored at 4 or 37 °C for up to
micromass pellet cultures. AA2P = ascorbic acid‐2‐phosphaterepeated supplementation (which would ultimately impose critical
manufacturing challenges when using a closed bioreactor system),
we investigated whether the continual presence of AA2P was neces-
sary to maintain a chondrogenic phenotype and for the production
of components required for engineered cartilage. This question was
addressed by using nasal chondrocyte pellet cultures in serum‐free
medium.
3.2 | Cell viability
Because AA is a potent antioxidant that prevents oxidative stress in
cells, the effect of its absence on cell viability was tested in micromass
pellet cultures under normoxic conditions. Terminal deoxynucleotidyl
TUNEL was similar in pellets cultured with (+AA2P and Daily AA2P)
or without AA2P (−AA2P), with only a few instances of DNA fragmen-
tation detected among all conditions with ITS (Figure 2a); whereas in
the absence of both AA2P and ITS (−AA2P −ITS), all cells exhibited
oxidative stress. In addition, the DNA content of all pellets cultured
with ITS was the same irrespective of AA2P supplementation, indicat-
ing that cell number was unaffected (Figure 2b).
3.3 | Gene expression and glycosaminoglycan
deposition
No significant differences were found in the expression of genes asso-
ciated with either chondrogenic differentiation (collagen Type II,
aggrecan, and sox‐9) or chondrocyte dedifferentiation (collagen Type
I and versican) irrespective of AA2P supplementation (Figure 3a). Saf-
ranin‐O staining of micromass pellets showed similar cell densities and
uniform GAG deposition irrespective of the AA2P supplementation
(Figure 3b). Negative control −AA2P −ITS pellets were filled with
extracellular matrix that was negative for GAG staining. Biochemical
quantification of pellets showed that the sGAG/DNA content was
consistent with histological assessment and unaffected by AA2P sup-
plementation. In contrast, −AA2P −ITS pellets had significantly lower
sGAG/DNA (Figure 3c).
3.4 | Collagen extracellular matrix
Because AA is a cofactor in the hydroxylation of proline during colla-
gen synthesis, we tested the effects of AA2P on collagen depositioncultures. (a) Concentration of AA2P in serum‐free medium (SF) or 10%
14 days. (b) Concentration of AA2P in spent serum‐free medium of
FIGURE 2 (a) TUNEL staining (red) and DAPI nuclear counterstaining (blue) of micromass pellets after 2 weeks of chondrogenic culture. Arrows
point toTUNEL positive staining. (Scale bar 50 μm). (b) DNA quantification of micromass pellets. Data are presented as mean ± standard deviation.
AA2P = ascorbic acid‐2‐phosphate; TUNEL = transferase dUTP nick end labelling [Colour figure can be viewed at wileyonlinelibrary.com]
FIGURE 3 Gene expression and glycosaminoglycan content following 2 weeks of micromass pellet culture. (a) The expression of genes
associated with differentiated (collagen Type II, sox‐9, aggrecan) and de‐differentiated chondrocytes (collagen Type I, versican) after 2 weeks of
chondrogenic differentiation. (b) Safranin‐O staining of histological sections of micromass pellets. (Scale bar indicates 200 μm). (c) sGAG/DNA of
micromass pellets normalized to +AA2P values of the same donor. Data are presented as mean ± standard deviation. (*indicates statistically
significant differences from other groups with p < .05). AA2P = ascorbic acid‐2‐phosphate; sGAG = sulphated glycosaminoglycan [Colour figure
can be viewed at wileyonlinelibrary.com]
ASNAGHI ET AL. 5and hydroxylation. Immunohistochemical analysis showed that
micromass pellets stained positive for both collagen Types II and I,
with intensities and staining patterns unaffected by AA2P supplemen-
tation (Figure 4). CollagenType I was distributed mainly on the edge ofthe pellets, while collagen Type II was abundantly present throughout
the whole pellet, except for a thin outer rim, indicating deposition of a
cartilage like matrix. Removal of ITS resulted in no positive collagen
Types II or I staining.
FIGURE 4 Collagen Types II and I immunohistochemistry of micromass pellets after 2 weeks of culture. (Scale bar indicates 200 μm).
AA2P = ascorbic acid‐2‐phosphate [Colour figure can be viewed at wileyonlinelibrary.com]
6 ASNAGHI ET AL.Quantification of pellet collagen Types II and I by specific immu-
noassays confirmed deposition of both proteins even in the absence
of AA2P. The amount of collagen Types II and I in −AA2P pellets were
34% less (p < .01) and 50% less (p < .001) than in +AA2P pellets,
respectively (Figure 5a,b). The amount of collagens in the Daily
AA2P pellet group were similar and not significantly different from
the +AA2P group. In contrast, −AA2P −ITS pellets contained signifi-
cantly less collagenType II and virtually no collagenType I. Post‐trans-
lational hydroxylation of collagens was confirmed by the
quantification of the hydroxyproline/collagen content in pellets, which
was similar for all experimental conditions, irrespective of the AA2P
condition (Figure 5c). In contrast, the hydroxyproline/collagen content
was significantly lower in negative control pellets (−AA2P −ITS).3.5 | Collagen secretion
Because removal of AA2P could affect deposition of collagen within
the extracellular matrix due to impaired collagen secretion, we used
high magnification immunofluorescence to assess intracellular and
extracellular collagen Type II accumulation. As seen in Figure 6, colla-
gen Type II was evenly distributed in the extracellular matrix, but no
intracellular retention of vesicle‐like structures staining positive for
collagen Type II could be observed, independent of the AA2P condi-
tion. No extracellular or intracellular collagen Type II was detected in
the negative control pellets (−AA2P −ITS).3.6 | Collagen fibril network
We investigated whether the absence of AA2P had an effect on the
collagen fibrils deposited within the micromass pellets. As seen in
Figure 6, SEM imaging of micromass pellets showed dense networks
of collagen fibrils, which appeared to have similar thicknesses and dis-
tributions for all AA2P conditions. In contrast, no collagen fibrils could
be observed in the negative control pellets (−AA2P −ITS).4 | DISCUSSION
In this work, we have shown that AA2P was rapidly degraded in
medium used for culture of engineered cartilage tissues. However,
when chondrocytes were cultured in 3D micromass pellets either with
or without AA2P, we found no significant differences in their
chondrogenic capacity in terms of gene expression and sGAG deposi-
tion. Interestingly, pellets cultured without AA2P contained abundant
collagenTypes II and I extracellular matrix. While the amount of these
collagens was significantly lower in −AA2P pellets than those cultured
with AA2P, the network of collagen fibers appeared quite similar.
AA is known to be an unstable component of cell culture medium
due to a fast degradation process catalysed by iron and copper ions
(Fisher & Naughton, 2004). AA2P, with the protective phosphate
group, has been shown to be more stable (Takamizawa et al., 2004);
however, the stability can be affected by specific components of the
culture medium. We have demonstrated that AA2P was stable in
serum‐free medium for up to 2 weeks when stored at either 4 °C or
37 °C. That stability was drastically reduced in medium containing
serum, likely due to the presence of phosphatases in the serum
(Chepda et al., 2001). When culturing chondrocytes in micromass pel-
lets, the AA2P concentration was reduced by half after 24 hr, even in
serum‐free medium. It is likely that membrane‐bound or secreted
phosphatases degraded AA2P to AA, which was then either rapidly
degraded or taken up by the cells (Takamizawa et al., 2004). To
account for the depletion of AA2P during culture, in subsequent
experiments, we included an experimental group in which the level
of AA2P was measured and adjusted daily to the initial concentration
(i.e., 100 μM) in order to assess the effects of a more constant level of
AA2P in the culture medium. While the number of cells would likely
have an impact on the level of AA2P depletion throughout culture,
the ratio of cell number to culture medium volume (1E + 06 cells/ml)
used in this study has clinical relevance, because it is the same ratio
used in the manufacturing of cartilage grafts for clinical studies
(Mumme et al., 2016).
FIGURE 5 Quantification of (a) collagen Type II, (b) collagen Type I,
and (c) the ratio of hydroxyproline to collagen, following 2 weeks of
micromass pellet culture. Values were normalized to the respective
value of +AA2P of the same donor. Data are presented as
mean ± standard deviation. (*indicates statistically significant
difference from +AA2P with p < .05). AA2P = ascorbic acid‐2‐
phosphate
ASNAGHI ET AL. 7Following 2 weeks of micromass pellet culture under normoxia,
we observed no differences in apoptosis, necrosis, or DNA content,
regardless of the AA2P supplementation regime. Endogenous
antioxidants such as glutathione have likely compensated for the
absence of AA2P and provided sufficient protection against reactive
oxygen and nitrogen species (Espinosa‐Diez et al., 2015).
We compared de‐differentiated monolayer expanded
chondrocytes with redifferentiated chondrocytes in micromass pellets
and found an upregulation of genes associated with chondrogenic dif-
ferentiation (collagenType II and aggrecan) in pellets. Interestingly, the
expression of all genes assessed, whether chondrogenic or not, was
similar for pellets cultured with or without AA2P. Biochemical and his-
tological assessments also indicated no differences between +AA2P,
Daily AA2P, or −AA2P pellets. In the presence of ITS, with or withoutAA2P, chondrocytes were rounded and embedded within lacunae and
surrounded by dense GAG matrix; indicating that the chondrogenic
capacity of human nasal chondrocytes was not significantly affected
by AA2P.
Immunohistochemical and ELISA assays confirmed that
chondrocytes could produce collagen Types II and I proteins in the
absence of AA2P, although to lesser extent than when cultured with
AA2P. Quantification of collagen Types II and I by ELISA enabled col-
lagen to be determined independent of hydroxyproline quantification
(Dickinson et al., 2005; Hollander et al., 1994), thus enabling the pro-
portion of hydroxyproline in collagens to be calculated. This calcula-
tion was based on the assumption that the majority of collagen in
pellets was Types II and I; however, it is possible that other collagens
(e.g., Types III and XII) were also present in small amounts
(Taylor et al., 2015). Additional biochemical analysis indicated that
the amount of hydroxyproline/collagen was similar for +AA2P, Daily
AA2P, −AA2P, suggesting that the enzyme proline hydroxylase was
functional even in the absence of AA2P. These findings are consistent
with previous studies demonstrating that AA was not essential as a
cofactor for prolyl hydroxylase under certain conditions. In fact,
mutant mice lacking the final enzyme for AA synthesis were shown
to have normal collagen production, and the absence of AA had no
direct effect on collagen hydroxylation in guinea pigs (Dickinson
et al., 2005; Parsons, Maeda, Yamauchi, Banes, & Koller, 2006;
Peterkofsky, 1991). Other molecules present in the medium such as
glutathione or cysteine may have compensated for the lack of a cofac-
tor, even if at a lower activity (Barnes & Kodicek, 1972). Indeed, lysyl
hydroxylase can function in the absence of AA for a short period
(Puistola, Turpeenniemi‐Hujanen, Myllyla, & Kivirikko, 1980). Alterna-
tively, AA could be recycled over long durations, which could also
explain why collagen production without AA supplementation has
been observed in vivo (McNulty, Stabler, Vail, McDaniel, & Kraus,
2005; Qutob, Dixon, & Wilson, 1998). Interestingly, no increase in col-
lagen deposition (Figure 4) or hydroxylation/collagen ratio (Figure 5)
was observed when maintaining the concentration of AA2P on a daily
basis close to initial levels (Daily AA2P), despite the observed reduc-
tion in available AA after 24 hr of pellet culture (Figure 1b). This indi-
cates that the applied regime of twice weekly medium exchanges was
sufficient to reach saturation of AA‐dependent mechanisms, before
available AA was completely diminished.
Despite similar gene expression, reduced amounts of collagen
Types II and I in −AA2P pellets could have resulted from inhibited col-
lagen secretion (Bentovim, Amarilio, & Zelzer, 2012). Based on immu-
nofluorescence staining for collagen Type II, no intracellular retention
of vessel‐like structures could be detected (Gelse et al., 2008), sug-
gesting collagen secretion may not have been significantly impaired
in the absence of AA2P. However, additional analyses should be per-
formed in order to more closely investigate potential impaired collagen
secretion, such as TEM imaging or an investigation of the unfolded
protein response.
The unique biomechanical features of articular cartilage largely
depend on its highly organized molecular and structural composition
(Buckwalter & Mankin, 1998). Based on SEM imaging, all micromass
pellets qualitatively appeared to have similar fiber thicknesses and dis-
tributions, regardless of AA2P supplementation. Together with the
FIGURE 6 (a) Cryosections of micromass pellets stained by immunofluorescence against collagen Type II (red) and DAPI nuclear counterstain
(blue). (Scale bar indicates 10 μm). (b) Scanning electron microscopy of micromass pellets showing the network of collagen fibrils. (Scale bar
indicates 300 nm). AA2P = ascorbic acid‐2‐phosphate; SEM = scanning electron microscopy [Colour figure can be viewed at wileyonlinelibrary.
com]
8 ASNAGHI ET AL.similar hydroxylation profiles, this suggests that the extracellular
matrix engineered with or without AA2P could potentially have similar
biomechanical properties (Berg & Prockop, 1973). This hypothesis
remains to be investigated in future studies. Furthermore, the analysis
of collagen crosslinks would provide insight into the integrity of colla-
gen fibrils in the absence of AA2P, because crosslink formation
requires hydroxylation of lysine residues, and hydroxylysine derived
immature crosslinks such as lysinonorleucine provide tensile strength
to collagen fibrils (Davison, 1989). Maturation of collagen crosslinks
into tri and tetravalent hydroxyl‐pyridinoline crosslinks increases colla-
gen fibril strength further (Reiser, Hennessy, & Last, 1987), but this
condensation reaction is unlikely to occur within 2 weeks of collagen
synthesis (Murdoch, Hardingham, Eyre, & Fernandes, 2016).
In this work, we have shown that de‐differentiated human nasal
chondrocytes cultured as micromass pellets without AA2P, could
redifferentiate and generate cartilaginous tissue. The engineered tis-
sues had similar properties to those generated in the presence of
AA2P, with the exception of lower collagen content. Although the
amount of collagenType II was reduced by 34% in the absence of AA,
the question remains whether this slight reduction in collagen content
would have any clinical impact. Clinical studies aimed at understanding
the effect of the maturation stage of engineered cartilage tissues on
cartilage repair will help to address the lingering question in cartilage
tissue engineering “how good is good enough?”. If engineered cartilage
grafts can be generatedwith sufficient properties to meet defined qual-
ity criteria without the use of unstable medium components such as
AA, bioreactor automation requirements can be greatly simplified,
thereby facilitating the development of a more compact, user‐friendly,
and cost‐effective bioreactor‐based manufacturing system.ACKNOWLEDGEMENTS
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